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Objectives: To match responsive neurostimulator (RNS) and polysomnographic data to determine if RNS detec-
tions and stimulations correlate with measurements of sleep disordered breathing and continuous glucosemea-
surements (CGM).
Materials and methods: In a patient with an RNS with detection/stimulation leads implanted bi-temporally
detection-stimulation counts were matched by time with coinciding polysomnogram and CGM data.
Results: Temporal dispersion of RNS DSC were independent of measures of sleep apnea, hypopnea or glucose.
Conclusion:Hippocampal nighttime responsive neurostimulation therapies did not appear toworsenmeasures of
normal or abnormal sleep.










The responsive neurostimulation system (RNS, NeuroPace, Moun-
tain View, CA) reduces self-reported seizure frequencies in patients
with drug-resistant focal epilepsy [1]. The RNS surveys electrocorticog-
raphy, which is trained to recognize physician-selected patterns associ-
ated with seizure onset, and then triggers electrical stimulation(s) or
therapies designed to help mitigate or ideally terminate seizure. Deliv-
ered therapies or detection-stimulation counts (DSC) can be used to
study treatment efficacies. For example, in the same patient we discuss
here, we were previously able to illustrate effects of mirtazapine on in-
creased RNS DSC over both an hourly and daily timeframe [2]. Contem-
porary RNS programming detects and delivers therapies generously. In
the open-label portion of the RNS pivotal trial [1] there was an average
of 1175 DSC per day [personal communication]. In this study we used a
similar technique to examine DSC and whether or not they correspond
to collected polysomnographic data either in sleep staging or measures
of sleep disordered breathing.
Obstructive sleep apnea (OSA) and epilepsy have high comorbidity
rates and sleep apnea may worsen seizure control [3,4]. Sleep distur-
bance and deprivation is known to reduce seizure threshold and there-
fore treatment for OSA can improve seizure control in patients with
drug-resistant epilepsy. During convulsive seizures in particular there
may be cessation of breathing, particularly during the tonic phase.
Independent of seizure-related apnea, it is not well known whether
undertreated epilepsy aggravates sleep apnea.
In the medical device literature the apnea hypopnea index (AHI), a
keymeasure of sleep apnea, increased after beginning vagus nerve stim-
ulation (VNS) therapy [4]. In addition, episodic apneas occurred more
frequently during VNS. A similar understanding of RNS effects on
sleep apnea has yet not been published. Of interest though is RNS data
that shows DSC to have a strong circadian pattern, peaking during noc-
turnal hours regardless of region of onset [5]. In that same study, long
nocturnal seizure episodes were increased depending on seizure onset
locations. Specifically, temporal neocortical and frontal lobe onsets
were more often at night while mesial temporal onsets were more
often during daytime.
2. Materials and methods
With informed patient consent, patient data were abstracted and
assessed from electronic medical records including RNS logs of DSC
and polysomnography (PSG), average DSC, apnea events and other
polysomnogram highlights, and stage of sleep were collected [Figs. 1
and 2]. Sleep was scored according to American Academy of SleepMed-
icine (AASM) criteria by a licensed sleep medicine technician and fur-
ther reviewed by a board certified physician specializing in sleep
medicine. RNS stimulation settings at the time of polysomnogram in-
cluded a current of 3.5 ma frequency of 100 Hz, a pulse width of 120
μs, and burst duration of 100 ms with an estimated charge density of
1.3 μC/cm2. Therapies 1–5 were all the same, and the electrode
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configuration and polarity of right and left hippocampal contacts was
negativewith the RNSdevice positive. Detection settings on both hippo-
campi included bandpass assessments with bands set between
2–125 Hz, amplitudes of 12–69% and surveillance durations of
0.256–0.640 s. When first programmed at these settings, post stimula-
tion therapy testing elicited no symptoms. Given the patient had a func-
tional continuous glucosemonitoring systemwith tissue glucose checks
every 5min (CGM, DEXCOM, SanDiego, CA), that convenience datawas
also examined in relation to the RNS and polysomnographic findings.
Statistical analysiswas formed using two-tailed t-tests or Pearson corre-
lation with significance p b 0.05.
3. Case report
A 45-year-old female with drug-resistant bitemporal epilepsy
underwent implantation of the RNS device in 2014 after failure of med-
ical and VNS therapies. Seizure types include audiogenic (Johnny Cash's
song Ring of Fire, for instance, would trigger focal seizures and poten-
tially convulsions) as well as focal impaired awareness seizures charac-
terized by automatisms of lip smacking and behavior arrest with rarer
progression to bilateral tonic-clonic seizures. Her ILAE classification is
focal aware and focal impaired awareness seizures with emotional, sen-
sory and behavior arrest with progression to bilateral tonic–clonic
seizures. A brother and a second cousin also have epilepsy, however
the family LG1 gene status is unknown. MRI scan pre-RNS showed me-
sial temporal blurring and size diminishment on the left. Comorbid con-
ditions include type I diabetes mellitus, depression, and insomnia. Her
RNS detections were recorded from two four-contact depth electrodes
placed over the left and the right hippocampus. Those locations were
chosen based on intracranial monitoring results suggesting hippocam-
pal involvement in seizure generation. Her VNS device, which histori-
cally produced no effect on seizure controls, remained off. A functional
insulin pump was used for the duration studied as well as a regularly
calibrated CGM.
Because of complaints of non-restorative sleep and excessive day-
time sleepiness, she underwent polysomnographic testing in an AASM
accredited lab. Sleep data was matched to RNS and CGM data during
polysomnography. Anti-seizure medications included topiramate, leve-
tiracetam, clobazam, clonazepam, and gabapentin and were dosed at
09:00 and 21:00. The patient was not on antidepressants during this
time period.
No clinical or electrographic seizureswere observed byRNS or the 6-
lead polysomnographic EEG. The RNS recorded many DSC throughout
the night [Fig. 1]. These were not analyzed by side of detection. DSC
failed to impact staging of sleep, with progression through various
sleep stages independent of DSC activities.
Fig. 1. Total number of detection-stimulation counts recorded by the RNS each hour during the sleep study combined with polysomnographic and glucose data. Glucose data appears as
both an hourly average and at time of apnea events and is in red.
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DSC counts show a marked increase between 05:00 and 07:00,
when hourly glucose averages were lowest at 80 and 74 mg/dL respec-
tively. Blood glucose levels averaged 110 mg/dL (range =
68–172 mg/dL) during the sleep study. The lowest number of DSC was
detected between midnight and 1 am, when 31 detections occurred
(we only have hourly recordings of DSC, not minute-by-minute data).
Blood glucose levels were recorded over that same hour averaged
114 mg/dL. DSC relationships show more stimulations with lower glu-
cose (Glucose mean 111 mg/dL, SD 29, DSC mean 68, SD 39, Pearson R
score = -0.685, p= 0.06.)
The PSG showed no significant sleep apnea [Fig. 1]. The AHI was
1.8 (an AHI of b5/h is considered normal). She slept for 6.6 h with a
normal sleep efficiency of 90%, sleep latency was 21 min, REM
sleep latency was prolonged (184.5 min). N1 sleep was 6.7% with
8.7 arousals for hour. REM sleep was reduced at 9% and stage N3
was increased at 38.6% of time. No significant heart rate or oxygen
derangements were noted. During the entire night, a mixture of ob-
structive apneas (#5), central apneas (#6), and one hypopnea were
recorded. All obstructive events occurred in stage II sleep over a
14-min period.
Most central apneas rapidly altered the sleep stage towards
wakefulness.
Glucose values as close to the exact time of events were also re-
corded [Fig. 1]. Levels of glucose with obstructive apnea glucose levels
(n = 5, average = 115 mg/dL, range = 115, SD = 0) were higher
than glucose levels with central apnea levels (n = 6 average
97 mg/dL, range 71–109, SD13.8, t = 4.88, p b 0.01 two-tailed t-test).
4. Discussion
In this patient, therewas noobvious link to RNS stimulations and de-
tections from bi-hippocampal locations on measures of sleep apnea or
sleep staging. Hourly DSC were highest when hourly glucose was low-
est.We are now studying those relationships between RNS stimulations
and glucose levels in separate work. Glucose levels, not DSC, appear to
be more related to apnea. Specifically, central apneas are associated
with lower glucose than obstructive apneas.
There are drawbacks to the study. First the patient does not have
sleep apnea and whether or not the RNS worsens (or improves) insom-
nia, controls of sleep apnea, or sleep staging is unclear, there is no inter-
nal control (i.e. baseline polysmonogram without her RNS device) for
comparison. Second, the time blocks available through RNS data access
do not permit a minute-by-minute breakdown of DSC. The period be-
tween 1 and 2 AM for instance, when the bulk of the obstructive apneas
and modest DSC occurred, cannot be further examined to see if DSC
cluster peri-, inter-, or immediately post-apnea. Similarly we can't
match the exact times of DSC to assess if central apneas are more likely
with frequent stimulation.We canmatch glucosewith apnea times, and
there may be a difference there, though we view that relationship with
some skepticism as all the obstructive events occurred in a 14-minute
window with an invariant glucose level (Fig. 1). Further work in a
broader population would need to clarify if central apneas consistently
occur with a lower or declining glucose than obstructive apneas. A crit-
icismof our statistical datawould be risks ofmultiple comparison errors
including comorbidities and the effects of medications on sleep. Effects
of her complex medication regimen on sleep staging. Finally, sleep
under laboratory conditions may have been atypical. In the Spencer
et al. study, DSC counts by time of day suggest an increase during
sleep, and decrease during wakefulness [5]. The patient's own DSC
data suggests that pattern is inverted, DSC are increased during daytime
(see days 1–6 in Fig. 2). If that pattern held for our patient, the results
may suggest that the patient had a sleep wake inversion, sleeping
more during the day, and yet complaining of insomnia at night. She
did not complain of daytime napping prior to the polysomnography,
though subsequent use of daytime neurostimulants (modafanil) caused
her more recent DSC to show amore typical increase during night-time
sleep and decrease during daytime (data not shown) with marked im-
provements in daytime somnolence.
Fig. 2.Detection stimulation counts recordedduring theweek of the sleep study. Thepolysomnogramwas done fromhour 2300day 6 into hour 0700day 7. The superimposed redmarkers
are time of day, 0–2300 h.
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We conclude that RNS effects on sleep seem to be minimal based
upon the patient's ECoG recorded from the hippocampal location. How-
ever, sleep staging like episodes of apnea may involve deep midline an-
atomical structures (pontine, medullary, thalamic, and hypothalamic)
that aremore remote from this patient's hippocampal DSC or be remote
from the patient's individual epileptogenic network. This would align
with earlier data on seizure Long Episodes recovered from hippocampal
locations showingminimal diurnal variation as compared to other loca-
tions of electrode placement [5]. In comparison, it is important to note
that brainstem and thalamic pathways are more involved with VNS
stimulations [3,4] which may provide greater anatomic specificity for
VNS effects on sleep apnea.
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